By historical standards, all three of these businesses are now bargains.
News & Analysis: Jazz Pharmaceuticals
The company's submitted an application for approval of JZP-258, a treatment for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy.
You might want to add a luxury e-tailer and a sleep-disorder specialist to your buy list.
Which biotech was a 37-bagger?
These stocks offer investors a good mix of stability and value.
Here is why Jazz Pharmaceuticals could survive the threat from generics for its top-selling product.
JAZZ earnings call for the period ending September 30, 2019.
The drugmaker delivered revenue and earnings beats thanks to continued momentum for sleep disorder drug Xyrem.
JAZZ earnings call for the period ending June 30, 2019.
Looking for bargains? You'll definitely want to check out these dirt-cheap healthcare stocks.